SCHEMBL21452688

SCHEMBL21452688

CC(=O)NC1CCN(c2ccnc(-c3ccc(F)c(OC(F)(F)F)c3)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMPD3 Q9NY59 3/20 0.43
▸ ITGB2 P05107 1/20 0.41
▸ ICAM1 P05362 1/20 0.41
▸ ITGAL P20701 1/20 0.41
▸ EPHX2 P34913 6/20 0.41
▸ CCNC P24863 2/20 0.41
▸ CDK8 P49336 2/20 0.41
▸ DDR1 Q08345 1/20 0.40
▸ SYK P43405 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.39
▸ SSTR1 P30872 1/20 0.39
▸ SSTR4 P31391 1/20 0.39
▸ SUV39H2 Q9H5I1 1/20 0.39
▸ MPL P40238 1/20 0.39
▸ HRH4 Q9H3N8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21433960 0.94 EPHX2 (0.46) SMPD3ITGB2ICAM1ITGALEPHX2
SCHEMBL21434012 0.89 SMPD3 (0.43) SMPD3ITGB2ICAM1ITGALEPHX2
SCHEMBL21433916 0.88 KMO (0.48) SMPD3ITGB2ICAM1ITGALEPHX2
SCHEMBL21433937 0.87 SMPD3 (0.43) SMPD3CCNCCDK8SUV39H2HRH4
SCHEMBL21434025 0.87 ITGB2 (0.41) SMPD3ITGB2ICAM1ITGALEPHX2
SCHEMBL21434058 0.87 SMPD3 (0.51) SMPD3ITGB2ICAM1ITGALEPHX2
SCHEMBL21434159 0.84 ITGB2 (0.43) SMPD3ITGB2ICAM1ITGALCCNC
SCHEMBL21434096 0.84 SYK (0.45) SMPD3ITGB2ICAM1ITGALEPHX2
SCHEMBL21434068 0.84 SMPD3 (0.52) SMPD3ITGB2ICAM1ITGALCCNC
SCHEMBL21434084 0.84 ITGB2 (0.45) SMPD3ITGB2ICAM1ITGALEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008302-B2 Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2021-05-18 — — US disclosed
US-20190308950-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308950-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN3B SMPD3 4779/4885ITGB2 1763/4885ICAM1 4616/4885
US-11008302-B2 Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN3B SMPD3 4753/4885ITGB2 1693/4885ICAM1 4534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback